Global Diacylglycerol O Acyltransferase 1 Market Size By Type (GSK-3008356, KR-69530), By Application (Metabolic Disorder, Gastrointestinantal), By Region, And Segment Forecasts, 2023 to 2032

The Global Diacylglycerol O Acyltransferase 1 (DGAT1) Market was valued at USD 620 million in 2023 and is projected to reach USD 1.12 billion by 2031, growing at a CAGR of 7.8% during the forecast period from 2023 to 2031. Diacylglycerol O Acyltransferase 1 is a crucial enzyme in triglyceride synthesis, playing a vital role in lipid metabolism and energy homeostasis. The increasing prevalence of metabolic disorders, rising demand for targeted obesity and type 2 diabetes treatments, and ongoing research in lipid biosynthesis are key factors driving the market growth. Additionally, pharmaceutical innovations and biotechnological advances in gene therapy and enzyme targeting are expanding the application scope of DGAT1 inhibitors.

Drivers:

1. Rising Incidence of Metabolic Disorders:

Global rates of obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) are increasing rapidly, driving the demand for novel therapeutic targets. DGAT1 plays a critical role in triglyceride synthesis, making it a promising target for managing lipid-related disorders.

2. Advances in Drug Discovery and Enzyme Inhibition:

Significant progress in enzyme inhibition technologies and molecular biology has enabled the development of selective DGAT1 inhibitors, enhancing treatment efficacy and reducing adverse effects.

3. Pharmaceutical R&D Investments:

Biopharmaceutical companies are increasingly investing in the research and development of DGAT1-related compounds, supported by funding from public health institutions and international collaborations.

Restraints:

1. Side Effects and Safety Concerns:

Clinical studies of some DGAT1 inhibitors have reported gastrointestinal disturbances and other off-target effects, posing challenges in achieving regulatory approval.

2. Regulatory Hurdles and Complex Clinical Trials:

The development of enzyme-targeted therapies requires rigorous clinical trials, which are time-consuming and subject to stringent regulatory oversight, slowing down product commercialization.

Opportunity:

1. Emerging Therapeutic Areas:

Beyond metabolic disorders, DGAT1 inhibitors show potential in treating acne, Alzheimer’s disease, and certain cancers, creating vast untapped market opportunities.

2. Expansion in Emerging Economies:

Rising healthcare expenditures, improving diagnostics, and increasing awareness of metabolic diseases in Asia-Pacific and Latin America offer promising growth prospects.

Market by System Type Insights:

Based on system type, the Small Molecule Inhibitors segment accounted for the largest share in 2023. These molecules are widely studied and represent the most advanced development stage for DGAT1-targeted therapies. Ongoing trials and successful outcomes are expected to further consolidate this segment’s dominance. Meanwhile, Gene Therapy-based Approaches are emerging as a high-growth segment due to advances in CRISPR and RNAi technologies.

Market by End-use Insights:

In terms of end-use, Pharmaceutical Companies held the largest share in 2023, driven by robust pipelines and targeted research in metabolic therapeutics. The Academic & Research Institutes segment is expected to grow at the fastest rate due to increased public and private funding for fundamental research on lipid metabolism.

Market by Regional Insights:

North America dominated the global DGAT1 market in 2023, attributed to a high prevalence of lifestyle-related diseases, advanced healthcare infrastructure, and strong R&D funding. Asia-Pacific is projected to witness the fastest growth during the forecast period, supported by rising health awareness, government initiatives, and increased focus on chronic disease management in countries like China and India.

Competitive Scenario:

Key players in the Global Diacylglycerol O Acyltransferase 1 Market include Pfizer Inc., Novartis AG, Eli Lilly and Company, Amgen Inc., AstraZeneca plc, Gilead Sciences Inc., Boehringer Ingelheim, and Ionis Pharmaceuticals. These companies are focusing on expanding their clinical trial portfolios, entering strategic partnerships, and adopting novel biotechnological approaches. For instance:

In 2024, Pfizer expanded its metabolic disorder research division with a focus on DGAT1 inhibition in type 2 diabetes.

Novartis initiated Phase II trials of its DGAT1 inhibitor targeting non-alcoholic steatohepatitis (NASH) in early 2025.

Ionis Pharmaceuticals announced a collaboration with a genomics institute to develop RNA-targeted DGAT1 therapeutics.

Scope of Work – Global Diacylglycerol O Acyltransferase 1 Market

Key Market Developments:

March 2024: Amgen filed a new patent for a dual DGAT1/PPARα modulator for lipid control.

January 2025: Boehringer Ingelheim announced a partnership with a digital health firm to monitor lipid biomarkers in DGAT1 clinical trials.

June 2023: AstraZeneca launched an AI-driven research initiative for lipid metabolism targeting, including DGAT1 pathway analysis.

FAQs:

1) What is the current market size of the Global Diacylglycerol O Acyltransferase 1 Market?

The market was valued at USD 620 million in 2023.

2) What is the major growth driver of the Global Diacylglycerol O Acyltransferase 1 Market?

Rising incidence of metabolic disorders and innovations in enzyme-targeted therapies.

3) Which is the largest region during the forecast period in the Global Diacylglycerol O Acyltransferase 1 Market?

North America is expected to remain the largest market through 2031.

4) Which segment accounted for the largest market share in the Global Diacylglycerol O Acyltransferase 1 Market?

The Small Molecule Inhibitors segment led the market in 2023.

5) Who are the key market players in the Global Diacylglycerol O Acyltransferase 1 Market?

Pfizer Inc., Novartis AG, Eli Lilly and Company, Amgen Inc., AstraZeneca plc, and Boehringer Ingelheim.

Let me know if you'd like this turned into a downloadable document.